- Home
- KALV vs ELVR Comparison
KALV vs ELVR Comparison
Compare KALV & ELVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALV | ELVR |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.7M | 903.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | KALV | ELVR |
|---|---|---|
| Price | $17.04 | $45.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 761.7K | 51.8K |
| Earning Date | 05-09-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000,000.00 | N/A |
| Revenue This Year | N/A | $90.03 |
| Revenue Next Year | N/A | $42.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $15.55 |
| 52 Week High | $19.00 | $69.99 |
Technical Indicators
Market Signals| Indicator | KALV | ELVR |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 39.61 |
| Support Level | $14.59 | $44.24 |
| Resistance Level | $17.30 | $59.05 |
| Average True Range (ATR) | 1.10 | 2.79 |
| MACD | -0.05 | -1.05 |
| Stochastic Oscillator | 53.88 | 25.34 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About ELVR Sayona Mining Limited American Depository Shares
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.